The Week in Review: Jan 27, 2017 – Feb 3, 2017

Friday, February 3, 2017 News Recap Hepatitis C and Rheumatic, Kidney & Heart Disease As you may remember there have been quite a few news items over the past few months about the extrahepatic effects of hepatitis C, which is more and more coming to be recognized as a multi-organ disease.  Not only is the hepatitis C virus (HCV) the cause of liver diseases in up to 170 million people worldwide, it also has many extrahepatic disease manifestation...

Health Canada Grants Priority Review to AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis AbbVie's New Drug Submission is supported by data from its global registrational clinical development program across all major HCV genotypes and in patients with specific treatment challenges MONTREAL, Feb. 1, 2017 /CNW/ - AbbVie, a global biopharmaceutical company, today announced it has sub...

AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis - 100 percent of patients achieved SVR12 in a modified intent-to-treat analysis - G/P is an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose com...